Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients

BACKGROUND: Patients with end-stage renal disease (ESRD) requiring intermittent haemodialysis (IHD) are at high risk of MRSA bacteraemia (MRSA-B) and often fail first-line therapy. The safety, effectiveness and optimal dosing of telavancin for MRSA-B in this patient population are unclear. OBJECTIVE...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Antimicrob Chemother
Päätekijät: Britt, Nicholas S, Tirmizi, Samad, Ritchie, David J, Topal, Jeffrey E, McManus, Dayna, Nizet, Victor, Casabar, Ed, Sakoulas, George
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5890690/
https://ncbi.nlm.nih.gov/pubmed/29244141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkx437
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia